Company Description
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders.
The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.
It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial.
Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024.
The company was founded in 2020 and is headquartered in Warren, New Jersey.
| Country | United States |
| Founded | 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Ryan Saadi |
Contact Details
Address: 15 Independence Boulevard, Suite #410 Warren, New Jersey 07059 United States | |
| Phone | 877 838 6436 |
| Website | tevogen.com |
Stock Details
| Ticker Symbol | TVGN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001860871 |
| CUSIP Number | 88165K101 |
| ISIN Number | US88165K1016 |
| Employer ID | 98-1597194 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. | Co-Founder, Chief Executive Officer and Chairperson |
| Kirti Desai CPA | Chief Financial Officer |
| Dr. Neal Flomenberg M.D. | Chief Scientific Officer and Global Research & Development Lead |
| Stephen Chen M.B.A. | Chief Technical Officer |
| Mittul Mehta | Chief Information Officer and Head of Tevogen.ai |
| Tapan V. Shah | Head of Investor Relations and Corporate Development |
| Sadiq Khan M.B.A. | Chief Commercial Officer and Interim Head of Tevogen Generics |
| David E. Banko CPA | Global Head of Government Affairs and Patient Access |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 30, 2025 | 8-K | Current Report |
| Jun 27, 2025 | 424B3 | Prospectus |
| Jun 26, 2025 | EFFECT | Notice of Effectiveness |
| Jun 23, 2025 | 424B3 | Prospectus |
| Jun 23, 2025 | 8-K | Current Report |
| Jun 20, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 9, 2025 | 144 | Filing |
| Jun 3, 2025 | 424B3 | Prospectus |
| Jun 3, 2025 | 8-K | Current Report |
| May 14, 2025 | 424B3 | Prospectus |